Your session is about to expire
← Back to Search
Unknown
Group 1 for Pain
Phase 1
Waitlist Available
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial tests the safety and effects of a drug on heart rhythm, how the body processes it, and how it affects the body.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Group 1Experimental Treatment3 Interventions
Participants will receive VX-548-matching placebo, moxifloxacin-matching placebo and VX-548 at different time points.
Group II: Group 2AActive Control3 Interventions
Participants will receive VX-548-matching placebo, moxifloxacin and moxifloxacin-matching placebo at different time points.
Group III: Group 2BActive Control3 Interventions
Participants will receive VX-548-matching placebo, moxifloxacin-matching placebo and moxifloxacin at different time points.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VX-548 Placebo
2023
Completed Phase 1
~80
VX-548
2022
Completed Phase 3
~3580
Moxifloxacin Placebo
2012
Completed Phase 3
~1570
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Vertex Pharmaceuticals IncorporatedLead Sponsor
255 Previous Clinical Trials
34,595 Total Patients Enrolled
20 Trials studying Pain
1,299 Patients Enrolled for Pain
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger